# Using Travelan to Boost Immune Response in Vitro to COVID-19

> **NCT04643561** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 5 (estimated)

## Conditions studied

- Covid19

## Interventions

- **OTHER:** Travelan OTC

## Key facts

- **NCT ID:** NCT04643561
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643561, "Using Travelan to Boost Immune Response in Vitro to COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*